Loading...
•
Sep 30, 2021
Celldex Q3 2021 Earnings Report
Celldex reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Key Takeaways
Celldex Therapeutics reported a net loss of $20.5 million, or ($0.45) per share, for the third quarter of 2021. The company's cash, cash equivalents and marketable securities were $423.1 million as of September 30, 2021, which they believe is sufficient to fund planned operations through 2025.
Reported compelling data from Phase 1b study of CDX-0159 in chronic inducible urticaria, including a 95% complete response rate.
Initiated a Phase 1 study of the subcutaneous formulation of CDX-0159 and opened enrollment in the Phase 1b study in prurigo nodularis.
Made significant progress across clinical pipeline including bispecific platform.
Cash, cash equivalents and marketable securities as of September 30, 2021 were $423.1 million.
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2021 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...